Skip to main content

Peer Review reports

From: Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study

Original Submission
10 Aug 2020 Submitted Original manuscript
16 Aug 2020 Author responded Author comments - Ana Elena Martin-Aguilar
Resubmission - Version 2
16 Aug 2020 Submitted Manuscript version 2
17 Nov 2020 Author responded Author comments - Ana Elena Martin-Aguilar
14 Sep 2020 Reviewed Reviewer Report
1 Nov 2020 Reviewed Reviewer Report
Resubmission - Version 3
17 Nov 2020 Submitted Manuscript version 3
6 Dec 2020 Author responded Author comments - Ana Elena Martin-Aguilar
Resubmission - Version 4
6 Dec 2020 Submitted Manuscript version 4
Publishing
8 Dec 2020 Editorially accepted
5 Jan 2021 Article published 10.1186/s12885-020-07720-5

You can find further information about peer review here.

Back to article page
\